Abiopharma

Qyuns Therapeutics Co., Ltd., a clinical-stage biotech company, engages in the research and development of biologic therapies for autoimmune and allergic diseases in the Peoples Republic of China. Its lead product candidates include QX002N, an interleukin (IL)-17A inhibitor, which is in Phase III clinical trial for the treatment of ankylosing spondylitis; and QX005N, a monoclonal antibody (mAb) blocking IL-4Ra that is in Phase III clinical trial for treating prurigo nodularis. The company also develops QX001S, which is an IL-12/L-23p49 inhibitor for psoriasis under the SAILEXIN brand. In addition, the company develops QX008N, a humanized IgG1 mAb targeting thymic stromal lymphopoietin that is in Phase Ib clinical trial to treat moderate-to-severe asthma and chronic obstructive pulmonary disease (COPD); QX004N, an IL-23p19 inhibitor, which is in Phase II clinical trial to treat psoriasis and Crohns disease; QX013N, a humanized IgG1 mAb targeting c-kit; QX006N, an IFNAR1-targeting mAb that is in Phase Ib clinical trial for the treatment of systemic lupus erythematosus; QX007N, a humanized IgG1 mAb targeting IL-33 for treating moderate-to-severe COPD and asthma; and QX010N, an IL-31R inhibitor for the treatment of pruritus. Further, it manufactures and sells pharmaceutical products; and provides technical consultation services.

Additional info from OTC:
Qyuns Therapeutics Co., Ltd., a clinical-stage biotech company, engages in the research and development of biologic therapies for autoimmune and allergic diseases in the Peoples Republic of China. Its lead product candidates include QX002N, an interleukin (IL)-17A inhibitor, which is in Phase III clinical trial for the treatment of ankylosing spondylitis; and QX005N, a monoclonal antibody (mAb) blocking IL-4Ra that is in Phase III clinical trial for treating prurigo nodularis. The company also develops QX001S, which is an IL-12/L-23p49 inhibitor for psoriasis under the SAILEXIN brand. In addition, the company develops QX008N, a humanized IgG1 mAb targeting thymic stromal lymphopoietin that is in Phase Ib clinical trial to treat moderate-to-severe asthma and chronic obstructive pulmonary disease (COPD); QX004N, an IL-23p19 inhibitor, which is in Phase II clinical trial to treat psoriasis and Crohns disease; QX013N, a humanized IgG1 mAb targeting c-kit; QX006N, an IFNAR1-targeting mAb that is in Phase Ib clinical trial for the treatment of systemic lupus erythematosus; QX007N, a humanized IgG1 mAb targeting IL-33 for treating moderate-to-severe COPD and asthma; and QX010N, an IL-31R inhibitor for the treatment of pruritus. Further, it manufactures and sells pharmaceutical products; and provides technical consultation services.